Sera Prognostics IncChange company Symbol lookupSelect an option...SERA Sera Prognostics IncSPCE Virgin Galactic Holdings IncBBLG Bone Biologics CorpRPT RPT RealtyCLM Cornerstone Strategic Value FundRCI Rogers Communications IncADRA Adara Acquisition CorpEVTC Evertec IncOPEN Opendoor Technologies IncXAIR Beyond Air IncGo
Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 659.17x
- Price/Book (MRQ)
- 0.55x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Gregory C. CritchfieldChmn.
- Jay M. MoyesCFO
- Robert Gardner HarrisonCIO
- Jay BonifaceCSO
- Benjamin G. JacksonCounsel
Address
- 2749 E. Parleys Way, Suite 200
- Salt Lake City, UT 84109
- Phone: (801) 505-0278
- Fax: (302) 655-5049
- https://www.seraprognostics.com/
Insider Trading
During the most recent quarter, 8K shares were bought, and 60K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.